SUNRAY-01, A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First- Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum regardless of PD-L1 Expression.

PI: Dott. Giuseppe Lo Russo 

The study consists of 2 parts: A and B. The patient at the doctor's discretion can participate in either of the 2 parts. 

In Part A there are two groups of patients who could be assigned:  

- pembrolizumab and olomorasib 

- pembrolizumab and placebo 

Part B will explore whether the addition of the investigational oral drug (olomorasib) to the standard of care drugs (pembrolizumab, pemetrexed, cisplatin or carboplatin) administered intravenously helps to control the cancer over a longer period of time.  

Two groups of patients could be assigned to Part B:  

- pembrolizumab + olomorasib + chemotherapy 

- pembrolizumab + placebo + chemotherapy  

All patients will have a 1 in 2 (50%) chance of receiving either olomorasib or placebo.